An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions

Lung Cancer

Volumn 26, Issue 3, 1999, Pages 149-155

  Seemann, Marcus D ^a   Beinert, Thomas ^b   Fürst, Heinrich ^a   Fink, Ulrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Carcinoembryonic antigen (CEA); Cytokeratin 19 fragment marker (CYFRA 21 1); Lung cancer, tumour marker; Lung, solitary pulmonary lesion; Lung, tumour marker; Neuron specific enolase (NSE)

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG INJURY; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; COIN LESION, PULMONARY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033491422     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00084-7     Document Type: Article

References (28)

1. Akoun G.M., Scarna H.M., Milleron B.J., Benichou M.P., Herman D.P. Serum neuron specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest. 1:1985;39-43.
2. Bates J., Rutherford R., Divilly M., Finn J., Grimes H., O'Muircheartaigh I., Gilmartin J.J. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur. Respir. J. 10:1997;2535-2538.
3. Bates S.E. Clinical applications of serum tumour markers. Ann. Intern. Med. 115:1991;623-638.
4. Bergmann B., Brezicka F.T., Engström C.P., Larsson S. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur. J. Cancer. 29A:1993;198-202.
5. Buccheri G.F., Violante B., Sartoris A.M., Ferrigno D., Curcio A., Vola F. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer. 57:1986;2389-2396.
6. Davis E.W., Peabody J.W., Katz Jr S. The solitary pulmonary nodule. A ten year study based on 215 cases. J. Thoracic Surg. 32:1956;728-771.
7. Ebert W., Dienemann H., Fateh-Moghadam A., Scheulen M., Konietzko N., Schleich T., Bombardieri E. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Eur. J. Clin. Chem. Clin. Biochem. 32:1994;189-199.
8. Ferrigno D., Buccheri G. Clinical applications of serum markers for lung cancer. Respir. Med. 89:1995;587-597.
9. Fleischhacker M., Beinert T. Tumour markers-new aspects of an old discussion? Eur. J. Med. Res. 4:1999;144-148.
10. Gail M.H., Eagan R.T., Feld R., Ginsberg R., Goodell B., Hill L., Holmes E.C., Lukeman J.M. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer. 54:1984;1802-1813.
11. Gupta N.C., Frank A.R., Dewan N.A. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-Fluoro-2-deoxy-D-glucose. Radiology. 184:1992;441-444.
12. Gurney J.W. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. Radiology. 186:1993;405-413.
13. Hittmair K., Eckersberger F., Klepetko W., Helbich T., Herold C.J. Evaluation of solitary pulmonary nodules with dynamic contrast-enhanced MR imaging-a promising technique? Magn. Reson. Imaging. 13:1995;923-933.
14. Icard P., Regnard J.F., Essomba A., Panebianco V., Magdeleinat P., Levasseur P. Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann. Thorac. Surg. 54:1994;811-814.
15. Khouri N.F., Meziane M.A., Zerhouni E.A., Fishman E.K., Siegelman S.S. The solitary pulmonary nodule: assessment, diagnosis, and management. Chest. 91:1987;128-133.
16. Lai R.S., Hsu H.K., Lu J.Y., Ger L.P., Lai N.S. CYFRA 21.1 enzyme-linked immunosorbent assay: evaluation as a tumour marker in non-small cell lung cancer. Chest. 109:1996;995-1000.
17. Murakai M., Tohda Y., Iwanga T., Uejima H., Nagasaka Y., Nakajima S. Assessment of serum CYFRA 21.1 in lung cancer. Cancer. 77:1996;1274-1277.
18. Niklinski J., Furman M., Chyczewska E., Chyczewski L., Rogowski F., Laudanski J. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur. Respir. J. 8:1995;291-294.
19. Plebani M., Basso D., Navaglia F., De Paoli M., Tommasini A., Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br. J. Cancer. 72:1995;170-173.
20. Präuer H.W., Helmberger H., Weber W. Diagnosis of bronchial carcinoma. Radiologe. 38:1998;256-262.
21. Pujol J.L., Grenier J., Daures J.P., Daver A., Pujol H., Michel F.B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer. Res. 53:1993;61-66.
22. Rastel D., Ramaioli A., Cornillie F., Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer: report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur. J. Cancer. 30A:1994;601-606.
23. Siegelman S.S., Zerhouni E.A., Leo F.P., Khouri N.F., Stitik F.P. CT of the solitary pulmonary nodule. A.J.R. 135:1980;1-13.
24. Stieber P., Dienemann H., Hasholzner U., Müller C., Poley S., Hofmann K., Fateh-Moghadam A. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur. J. Clin. Chem. Clin. Biochem. 31:1993;689-694.
25. Takada M., Masuda N., Matsuura E., Kusunoki Y., Matui K., Nakagawa K., Yana T., Tuyuguchi I., Oohata I., Fukuoka M. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br. J. Cancer. 71:1995;160-165.
26. Viñolas N., Molina R., Galán M.C., Casas F., Callejas M.A., Filella X., Grau J.J., Ballesta A.M., Estape J. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer. Res. 18:1998;631-634.
27. World Health Organization. The World Health Organization Histological Typing of Lung Tumours. Am J Clin Pathol 1982;77:123-136.
28. Yankelevitz D.F., Henschke C.I. Does 2-year stability imply that pulmonary nodules are benign? A.J.R. 168:1997;325-328.